Dr Marianne Donald (PhD, MSc, BSc (Hons))

Thesis title: Metabolomic approaches to identify pathophysiological biomarkers of ischaemic stroke

Background

Dr Marianne Donald completed her PhD in Cardiovascular Science through the MRC Precision Medicine Doctoral Training Programme, a collaborative effort between the University of Edinburgh and the University of Glasgow. Her research specialises in applying metabolomics to uncover pathophysiological biomarkers of ischaemic stroke, contributing to improved diagnosis and translational outcomes in cardiovascular health.

Qualifications

  • PhD Cardiovascular Science (Precision Medicine)
  • MSc Precision Medicine and Pharmacological Innovation - with Distinction
  • BSc (Hons) Pharmacology - First Class

Undergraduate teaching

Dr Donald contributes to undergraduate education across the medical and life sciences curricula. Her teaching responsibilities include 3rd-year Pharmacology, where she is actively involved in course content development. Additionally, she has delivered teaching to 1st-year Medical students as well as 2nd- and 3rd-year Life Sciences students.

Postgraduate teaching

Dr Donald is involved in postgraduate curriculum design and teaching, contributing to the development of new Master's courses in Cardiovascular Science. She also participates in broader curriculum development initiatives across postgraduate biomedical and clinical programs.

Current research interests

Precision medicine, stroke pathophysiology, metabolomics, vascular research, epidemiological data managment and analysis

Past research interests

Pharmacology, stroke research, stratified medicine

Project activity

Project Title: Metabolomic Approaches to Identify Pathophysiological Biomarkers of Ischaemic Stroke

Stroke is the second leading cause of death globally and the leading cause of disability. This project focused on ischaemic stroke, investigating the cascade of biochemical changes that occur following oxygen and nutrient starvation due to blood vessel occlusion. By examining metabolomic alterations and their contribution to stroke pathology, the research aims to identify novel diagnostic and prognostic biomarkers to improve early stroke recognition and advance therapeutic understanding.